Integrated Cancer Repository for Cancer Research (iCaRe2)

April 28, 2026 updated by: University of Nebraska
The iCaRe2 is a multi-institutional resource created and maintained by the Fred & Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, high-risk individuals, and normal controls. The distinct characteristic of the iCaRe2 is its geographical coverage, with a significant percentage of small and rural hospitals and cancer centers. The iCaRe2 advances comprehensive studies of risk factors of cancer development and progression and enables the design of novel strategies for prevention, screening, early detection and personalized treatment of cancer. Centers with expertise in cancer epidemiology, genetics, biology, early detection, and patient care can collaborate by using the iCaRe2 as a platform for cohort and population studies.

Study Overview

Status

Recruiting

Conditions

Detailed Description

The integrated Cancer Repository for Cancer Research (iCaRe2 http://icare2.unmc.edu) is a unique sociotechnical resource for the collection and management of cancer and health-related data at the Fred & Pamela Buffett Cancer Center at University of Nebraska Medical Center (UNMC). The iCaRe2 is a multi-center, semantically interoperable and easily customizable cancer data resource, which is aimed at collecting, managing, mining and sharing the comprehensive, multi-dimensional cancer-related data on cancer patients and biospecimens (such as tumor specimens, germ line DNA, serum, urine, and plasma) collected from those individuals.

The iCaRe2 has been developed as an expansion of the biocomputing framework that initially included four multi-center collaborative registries: Pancreatic Cancer Collaborative Registry (PCCR), Breast Cancer Collaborative Registry (BCCR), Thyroid Cancer Collaborative Registry (TCCR), and Great Plains Health Informatics Database (GPHID; to enroll subjects with no history of cancer diagnosis at time of enrollment). The repository now includes: Thoracic Oncology Collaborative Registry (TOCR), GenitoUrinary Cancer Collaborative Registry (GUCARE), Head and Neck Cancer Collaborative Registry (HNCCR), Gastrointestinal & Abdominal Cavity Cancer Collaborative Registry (GACCaRe), Central Nervous System Tumor Collaborative Registry (CTCR), Leukemia and Myeloid Neoplasm Registry (LEMN) , Gynecological Cancer Collaborative Registry (GCCR), Sarcoma Collaborative Registry (SARCR), Melanoma Collaborative Registry (MELCR), Plasma Cell Dyscrasias Collaborative Registry (PDCR), Neuroendocrine Collaborative Registry (NETR), Non-Melanoma Skin Cancer Registry (NMSC) and Auxiliary Cancer Registry (ACR).

The iCaRe2 group elected to use a "confederation model", as opposed to a traditional registry or network model. The major advantages of a confederation model include the flexibility to use selected Centers for different research projects based on a Center's resources and expertise and the ability to have different strategies to address various research questions. A web-based registry iCaRe2 was developed and made available to any Center to participate in data collection and storage of cancer related data. The iCaRe2 provides a HIPAA compliant, secure, efficient and user-friendly mechanism for data and validation; utilization of standard vocabulary and data elements; and ad-hoc data reporting capabilities. The iCaRe2 serves as a collaboration platform for studies (including clinical trials) performed in centers with expertise in cancer biology, pathology, epidemiology, genetics, early detection, and patient care.

Study Type

Observational

Enrollment (Estimated)

999999

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • United States
    • Colorado
      • Greenwood Village, Colorado, United States, 80111
        • Recruiting
        • Advent Health
        • Contact:
        • Principal Investigator:
          • Mohammed Salhab, MD
    • Connecticut
      • Manchester, Connecticut, United States, 06040
        • Recruiting
        • Hartford HealthCare Cancer Institute at Manchester Medical Hospital
        • Principal Investigator:
          • Leslie Juliani, BSN, RN, OCN, CBCN
        • Contact:
    • Florida
      • Daytona Beach, Florida, United States, 32117
        • Recruiting
        • Florida Hospital Memorial Medical Center
        • Contact:
        • Principal Investigator:
          • Erik Harris, MD
      • DeLand, Florida, United States, 32720
        • Recruiting
        • Florida Hospital DeLand
        • Contact:
        • Principal Investigator:
          • Erik Harris, MD
      • Orange City, Florida, United States, 32763
        • Recruiting
        • Florida Hospital FISH
        • Contact:
        • Principal Investigator:
          • Erik Harris, MD
      • Palm Coast, Florida, United States, 32164
        • Recruiting
        • Florida Hospital Flagler
        • Contact:
        • Principal Investigator:
          • Erik Harris, MD
      • Tallahassee, Florida, United States, 32308
        • Recruiting
        • Tallahassee Memorial Hospital
        • Contact:
    • Illinois
      • Aurora, Illinois, United States, 60504
      • Yorkville, Illinois, United States, 60560
        • Recruiting
        • Rush-Copley Healthcare Center
        • Contact:
        • Principal Investigator:
          • Joseph T Meschi, MD
    • Indiana
      • Fort Wayne, Indiana, United States, 46845
        • Recruiting
        • Parkview Research Center
        • Principal Investigator:
          • Melanie Clark, MD
        • Contact:
        • Principal Investigator:
          • Brian Johnson, MD
    • Iowa
      • Council Bluffs, Iowa, United States, 51503
        • Recruiting
        • Methodist Jennie Edmundson Hospital
        • Contact:
          • Michael Zlomke, MD
          • Phone Number: 712-396-4117
        • Contact:
      • Waterloo, Iowa, United States, 50702
        • Recruiting
        • Covenant Medical Center, Inc
        • Principal Investigator:
          • Mukund Nadipuram, MD
        • Contact:
    • Kansas
      • Overland Park, Kansas, United States, 66213
    • Maryland
      • Randallstown, Maryland, United States, 21133
        • Recruiting
        • Northwest Hospital
        • Contact:
        • Principal Investigator:
          • Qiwei Gai, MD
      • Westminster, Maryland, United States, 21157
        • Recruiting
        • William E. Kahlert Regional Cancer Center
        • Contact:
        • Principal Investigator:
          • Melissa Loomis
    • Massachusetts
      • Holyoke, Massachusetts, United States, 01040
        • Recruiting
        • Holyoke Medical Center
        • Contact:
        • Principal Investigator:
          • Zubeena Mateen, MD
    • Minnesota
      • Aitkin, Minnesota, United States, 56431
        • Recruiting
        • Riverwood Healthcare Center
        • Principal Investigator:
          • Bret Friday, MD, PhD
        • Contact:
      • Brainerd, Minnesota, United States, 56401
        • Recruiting
        • Essentia Health-St. Joseph's Medical Center
        • Principal Investigator:
          • Bret Friday, MD
        • Contact:
      • Duluth, Minnesota, United States, 55805
        • Recruiting
        • Essentia Health - Duluth Clinic
        • Principal Investigator:
          • Bret Friday, MD, PhD
        • Contact:
      • Duluth, Minnesota, United States, 55805
        • Recruiting
        • St. Luke's Hospital of Duluth
        • Principal Investigator:
          • Anne Silva-Benedict, MD
        • Contact:
      • Fergus Falls, Minnesota, United States, 56537
        • Recruiting
        • Lake Region Healthcare
        • Principal Investigator:
          • Bret Friday, MD
        • Contact:
    • Missouri
      • Kansas City, Missouri, United States, 64111
        • Recruiting
        • Saint Luke's Cancer Institute
        • Principal Investigator:
          • Addison Tolentino, MD
        • Contact:
      • Kansas City, Missouri, United States, 64086
        • Recruiting
        • Saint Luke's Cancer Institute, East
        • Principal Investigator:
          • Addison Tolentino, MD
        • Contact:
      • Kansas City, Missouri, United States, 64118
        • Recruiting
        • Saint Luke's Cancer Institute, Kansas City North
        • Principal Investigator:
          • Addison Tolentino, MD
        • Contact:
      • Liberty, Missouri, United States, 64068
        • Recruiting
        • Saint Luke's Cancer Institute, Liberty
        • Principal Investigator:
          • Addison Tolentino, MD
        • Contact:
      • North Kansas City, Missouri, United States, 64116
        • Recruiting
        • North Kansas City Hospital
        • Principal Investigator:
          • John Park, MD
        • Contact:
      • Saint Joseph, Missouri, United States, 64507
        • Recruiting
        • Heartland Regional Medical Center dba Mosaic Life Care
        • Principal Investigator:
          • Juliet Gyamfua Appiah, MD
        • Contact:
    • Montana
      • Bozeman, Montana, United States, 59715
        • Recruiting
        • Bozeman Health Deaconess Hospital
        • Principal Investigator:
          • Justin Thomas, MD
        • Contact:
    • Nebraska
      • Hastings, Nebraska, United States, 68901
        • Recruiting
        • Mary Lanning Healthcare, Morrison Cancer Center
        • Contact:
      • Norfolk, Nebraska, United States, 68701
        • Recruiting
        • Faith Regional Health Services, Carson Cancer Center
        • Contact:
        • Sub-Investigator:
          • Rahib C Fahed, MD
        • Sub-Investigator:
          • Irena Popa, MD
      • North Platte, Nebraska, United States, 69101
        • Recruiting
        • Great Plains Regional Medical Center
        • Principal Investigator:
          • Kartik Anand, MD
        • Contact:
      • Omaha, Nebraska, United States, 68198
        • Recruiting
        • University of Nebraska Medical Center
        • Principal Investigator:
          • Kurt Fisher, MD, PhD
        • Contact:
      • Omaha, Nebraska, United States, 68114
        • Recruiting
        • Methodist Estabrook Cancer Center
        • Contact:
          • Russell Smith, MD
        • Contact:
      • Omaha, Nebraska, United States, 68114
        • Recruiting
        • Nebraska Methodist Health System
        • Contact:
        • Principal Investigator:
          • Aru Panwar, MD
    • New York
      • Glens Falls, New York, United States, 12801
        • Recruiting
        • C.R. Wood Cancer Center, Glens Falls Hospital
        • Contact:
          • Aqeel Gillani, MD
          • Phone Number: 518-926-6701
        • Sub-Investigator:
          • Aqeel Gillani, MD
        • Contact:
      • Utica, New York, United States, 13501
        • Recruiting
        • Faxton St. Luke's Healthcare, Mohawk Valley
        • Contact:
        • Principal Investigator:
          • Atul Butala, MD
    • North Carolina
      • Fayetteville, North Carolina, United States, 28304
        • Recruiting
        • Cape Fear Valley Health System
        • Contact:
          • Kenneth Manning, MD
        • Contact:
    • North Dakota
    • Ohio
      • Alliance, Ohio, United States, 44601
        • Recruiting
        • Aultman Alliance Community Hospital
        • Contact:
        • Principal Investigator:
          • Steven Eric Olyejar, MD
      • Canton, Ohio, United States, 44710
        • Recruiting
        • Aultman Hospital
        • Contact:
        • Principal Investigator:
          • Steven Eric Olyejar, MD
    • Wisconsin
      • Green Bay, Wisconsin, United States, 54305
        • Recruiting
        • Bellin Memorial Hospital
        • Principal Investigator:
          • Hassan Tahsildar, MD
        • Contact:
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

19 years to 110 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

Any individual who meets the eligibility criteria will be invited to participate in iCaRe2.

Description

Inclusion Criteria

  • Diagnosis/history of cancer
  • Risk for developing cancer or suspicious clinical findings
  • No history of cancer (normal control registry)
  • Able to provide informed consent
  • 19 years of age or older
  • English or Spanish speaking individuals

Exclusion Criteria

  • Unable to provide informed consent because of cognitive impairment
  • Non-English or non-Spanish speaking individuals

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Prospective

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Development and Implementation of a Web-based Cancer Collaborative Registry
Time Frame: 86 years
This is a registry that will continue to accrue participants indefinitely.
86 years

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Procurement and Banking of Excess Biological Material for Future Analysis
Time Frame: 86 years
This is a registry that will continue to accrue participants indefinitely.
86 years

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Collection and Banking of Blood, DNA, and Urine Samples for Future Studies
Time Frame: 86 years
This is a registry that will continue to accrue participants indefinitely.
86 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of Nebraska

Investigators

  • Principal Investigator: Kurt Fisher, MD, PhD, University of Nebraska

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 1, 2013

Primary Completion (Estimated)

December 1, 2099

Study Completion (Estimated)

December 1, 2099

Study Registration Dates

First Submitted

December 2, 2013

First Submitted That Met QC Criteria

December 10, 2013

First Posted (Estimated)

December 16, 2013

Study Record Updates

Last Update Posted (Actual)

May 5, 2026

Last Update Submitted That Met QC Criteria

April 28, 2026

Last Verified

June 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 0253-13-EP

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

All data and/or specimen request have to be made to the Principal Investigator of the center and follow the Human Subject Protection guidelines and policy.

IPD Sharing Time Frame

as long as the registry is open

IPD Sharing Access Criteria

Institutional Review Board approval to analyze data for separate study

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • ICF

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Melanoma

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Argentina

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe